18264-Gall Bladder Cancer-NA-3

Gall Bladder Cancer

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number:

  • Address

400 Patroon Creek Blvd, Suite 1
Albany, NY 12206
P: (518) 489-0044

Search by practice name, trial titles, indicators and specific disease types.